Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2023, Qiagen (QGEN) reported revenue of $475.89 million, down 4.8% over the same period last year. EPS came in at $0.50, compared to $0.53 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $471.47 million, representing a surprise of +0.94%. The company delivered an EPS surprise of +2.04%, with the consensus EPS estimate being $0.49.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Molecular Diagnostics: $254 million versus the two-analyst average estimate of $253.73 million.
Revenue- Life Sciences: $221 million compared to the $219.63 million average estimate based on two analysts.
Sales by Product Groups- Sample technologies: $160 million versus the two-analyst average estimate of $162.91 million.
Sales by Product Groups- Diagnostic solutions: $179 million versus $166.49 million estimated by two analysts on average.
Sales by Product Groups- Diagnostic solutions- QuantiFERON: $110 million versus the two-analyst average estimate of $99.88 million.
Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $20 million compared to the $21.32 million average estimate based on two analysts.
Sales by Product Groups- Other: $14 million versus $14.63 million estimated by two analysts on average.
Sales by Product Groups- PCR / Nucleic acid amplification: $68 million compared to the $66.96 million average estimate based on two analysts.
Sales by Product Groups- Genomics / NGS: $55 million versus the two-analyst average estimate of $59.83 million.
Sales by Product Groups- Diagnostic solutions- Other: $41 million versus $35.27 million estimated by two analysts on average.
Net Sales- Non-Covid product groups: $442 million versus the two-analyst average estimate of $436.77 million.
Net Sales- Covid-19 product groups: $34 million versus $34.04 million estimated by two analysts on average.
View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned -10.8% over the past month versus the Zacks S&P 500 composite's -3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
